secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093976
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Q2 net loss $50.3M ($0.21/sh); cash $251.6M; operating burn target <$200M
------------------------------------------------------------------------------

- Net loss $50.3M ($0.21 per share), improved from $114M loss ($0.59) in Q2 2023.
- Cash and equivalents $251.6M; expects 2024 operating cash burn below $200M.
- Four clinical trials ongoing across seven indications; initial data expected in 2024 for SC291, SC262, and UP421.
- R&D expenses decreased to $60.9M (Q2 2024) from $73.0M (Q2 2023) due to strategic repositioning.
- Non-GAAP operating cash burn for H1 2024 was $104.6M vs $136.5M in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024093976/0000950170-24-093976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024093976/sana-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer